









Markets
/
Stocks
/
nasdaq-ikt
/

Inhibikase Therapeutics Inc

IKT



View Detailed Chart

1.640USD

-0.080-4.65%

Market hours （ET）Quotes delayed by 15 min

122.68MMarket Cap

3.48P/E TTM



Inhibikase Therapeutics Inc

1.640

-0.080-4.65%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-4.65%

5 Days

+6.49%

1 Month

+10.07%

6 Months

-1.20%

Year to Date

-49.54%

1 Year

-48.75%

View Detailed Chart

TradingKey Stock Score of Inhibikase Therapeutics Inc

Currency: USD Updated: 2025-12-19

Key Insights

Inhibikase Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 87/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Inhibikase Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

87 / 404

Overall Ranking

203 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

7.000

Target Price

+386.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Inhibikase Therapeutics Inc Highlights

StrengthsRisks

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is 3.65, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 54.77M shares, increasing 1.58% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.27M shares of this stock.